Pr Jean-Bernard Fourtillan answers questions from Pr Henri Joyeux

A non-profit endowment fund for your health

Professors Jean-Bernard Fourtillan and His friends have decided to unite their efforts in order to announce to the general public, at the same time as to healthcare professionals and to researchers, this essential discovery and the medicinal products (single- or dual-compartment patches), in the process of being prepared, which result therefrom.

They created a non-profit endowment fund, the Josefa Fund, to which were given, in their totality, the intellectual property rights to the medicinal product patents resulting from this discovery.

> Read more

This discovery
revolutionises
the understanding
and treatment
of neurological diseases

Available Publications

  • The book - 216 pages.
    All the scientific
    explanations
  • The brochure
    52 illustrated plates with comments
> Discover

Valentonin : key to the discovery

1958-mltA.B. LERNER discovered
Melatonin
Neuroprotective hormone

1961-6mhW.M. Mc ISAAC discovered
6-methoxy-harmalan
Wakefulness hormone

1994-vltJ-B FOURTILLAN discovered
 Valentonin
Sleep hormone

The discovery of
the Sleep-Wake system

makes it possible to understand, for the first time,
how our body functions, alternately in sleep mode
and in waking mode, in 24-hour periods.

Three hormones secreted by the pineal gland
during the night, melatonin (MLT),
6-methoxyharmalan (6-MH) and Valentonin (VLT),
protect our body and guarantee the regulation
of mental and vegetative life.

> Read more

The European (EP) and international (PCT) patents that protect the therapeutic applications of this discovery have been filed and been given in their entirety to the Josefa Fund.

A suitable galenic formulation of mixed patches (Valentonine + 6-Methoxy-Harmalan) has been obtained, and we have been able to manufacture mixed patches since September 2018. They will be used in the treatment of neurological diseases for which it is necessary to increase the secretion of these 2 pineal hormones: sleep disorders, nervous depressions, neurodegenerative diseases of Parkinson’s and Alzheimer’s.

But, officially, according to the regulatory requirements, we will not be able to start the clinical trials of the patches, at the patients in the 4 indications, only after having obtained the favorable opinions of the CPP (Committee of Protection of the People) and received the Authorizations of Experiment (that is to say, start clinical trials in patients) of the ANSM (National Agency for Drug Safety).

Our goal is to obtain Marketing Authorizations (AMM) by the end of 2019, so that mixed patches are on sale in pharmacies during 2020.